The effects in SMA3 patients are predominantly centered around amino acid metabolism, which, thus, emerges as a common feature of Nusinersen treatment in SMA patients across the spectrum of disease severity. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.